Skip to content

Aura Biosciences, Inc. AURA Free cash flow yield

Free cash flow yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3%-2.1pp
Merck & Co. logo
Merck & Co.MRK
4.7%-2.8pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-3.8%-1.6pp
UroGen Pharma logo
UroGen PharmaURGN
-19%-1.7pp
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-3%-1.4pp
CG Oncology logo
CG OncologyCGON
-2.8%-0.7pp

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Calculated from Aura Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s free cash flow yield?
Aura Biosciences, Inc. (AURA) reported free cash flow yield of -21.4% in Q1 2026.
How has Aura Biosciences, Inc.'s free cash flow yield changed year-over-year?
Aura Biosciences, Inc.'s free cash flow yield increased by 21.5% year-over-year, from -27.2% to -21.4%.
What is the long-term trend for Aura Biosciences, Inc.'s free cash flow yield?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s free cash flow yield has grown at a 37.1% compound annual growth rate (CAGR), from -7% to -24.6%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.